Study of of VX-659 in healthy volunteers.

Trial Profile

Study of of VX-659 in healthy volunteers.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Jan 2017

At a glance

  • Drugs VX 659 (Primary) ; Ivacaftor; Tezacaftor
  • Indications Cystic fibrosis
  • Focus Adverse reactions
  • Most Recent Events

    • 08 Jan 2017 According to a Vertex Pharmacuticals media release, status changed from planning to recruiting.
    • 25 Nov 2016 New trial record
    • 25 Oct 2016 According to Vertex Pharmaceuticals media release, this study is expected to begin by the end of 2016 .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top